EUVIMEDAtrasti EUVIMED
Multizentrische StudieKohortenstudieOpen access · CC BY-NC 4.0

Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study

Péter Bacsur iD, Daniel Shaham, Zuzana Serclova iD, Tamás Resál iD, Bernadett Farkas iD, Patrícia Sarlós iD, Pál Miheller iD, Nitsan Maharshak iD, Meir Zemel iD, Ariella Bar-Gil Shitrit iD, Shlomo Yellinek iD, Anita Bálint iD and 13 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18359 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Péter Bacsur and 24 co-authors. Institution: Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. Major MEDLINE topics: Crohn Disease, Mesenchymal Stem Cell Transplantation, Rectal Fistula. Cited 12 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Emberi Eroforrások Minisztériuma, Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking.

Aims

To examine the usability of darvadstrocel therapy in managing perianal CD.

Methods

We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression.

Results

Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported.

Conclusion

Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseMesenchymal Stem Cell TransplantationRectal FistulaHumansFemaleMaleRetrospective StudiesAdultTreatment OutcomeMiddle AgedPatient SatisfactionYoung AdultRemission InductionCohort Studies

Author keywords

Crohn's diseasedarvadstrocelmesenchymal stem cell treatmentperianal disease

Authors and institutions

  • Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
  • HCEMM-USZ Translational Colorectal Research Group, Szeged, Hungary.
  • IBD Unit, Tel Aviv Medical Center, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Surgical Department, Clinical IBD Center ISCARE, Prague, Czech Republic.
  • Surgical Department, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary.

ORCID profiles: Péter Bacsur, Zuzana Serclova, Tamás Resál, Bernadett Farkas, Patrícia Sarlós, Pál Miheller, Nitsan Maharshak, Meir Zemel, Ariella Bar-Gil Shitrit, Shlomo Yellinek, Anita Bálint, Anna Fábián, Renáta Bor, Zsófia Bősze, Emese Ivány, Zoltán Szepes, Klaudia Farkas, Illés Tóth, György Lázár, Aneta Tremerova, Petra Zuskova, Szabolcs Ábrahám, Tamás Molnár

Funding

  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • Emberi Eroforrások Minisztériuma
  • Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem
  • Horizon 2020 Framework Programme
  • Szegedi Tudományegyetem

Cite

APA

Bacsur, P., Shaham, D., Serclova, Z., Resál, T., Farkas, B., Sarlós, P., Miheller, P., Maharshak, N., Zemel, M., Shitrit, A. B., Yellinek, S., Bálint, A., Fábián, A., Bor, R., Bősze, Z., Ivány, E., Szepes, Z., Farkas, K., Tóth, I., …, & Molnár, T. (2025). Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18359

Vancouver

Bacsur P, Shaham D, Serclova Z, Resál T, Farkas B, Sarlós P, et al. Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18359

BibTeX
@article{Bacsur2025,
  author = {Bacsur, Péter and Shaham, Daniel and Serclova, Zuzana and Resál, Tamás and Farkas, Bernadett and Sarlós, Patrícia and Miheller, Pál and Maharshak, Nitsan and Zemel, Meir and Shitrit, Ariella Bar-Gil and Yellinek, Shlomo and Bálint, Anita and Fábián, Anna and Bor, Renáta and Bősze, Zsófia and Ivány, Emese and Szepes, Zoltán and Farkas, Klaudia and Tóth, Illés and Lázár, György and Vlkova, Katerina and Tremerova, Aneta and Zuskova, Petra and Ábrahám, Szabolcs and Molnár, Tamás},
  title = {Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18359}
}
Start for free →